With a market capitalization (market cap) of $4.29B — a measure of how much the company is worth — Enliven Therapeutics, Inc. is the 1537th most valuable company in Healthcare as of August 18, 2026. Shares trade at $60.07, up +0.90% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Visit websiteAs of August 18, 2026, Enliven Therapeutics, Inc. (ELVN) is worth $4.29B — this is its market capitalization, the total value of all its outstanding shares.
Enliven Therapeutics, Inc.’s market cap is $4.29B, which ranks it #1537 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Enliven Therapeutics, Inc. (ELVN) shares trade at $60.07, up 0.90% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025